National Cancer Registry

Definition	A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place (Jenson et al, 1991).
Objectives	- To measure cancer incidence - To describe cancer by time, place, persons and disease - To provide a national database for further epidemiological research
Case definition	Target cases are: - Incident cases by year of diagnosis - Malignant tumors confirmed by histopathology and/or hematology findings - Cancers of all sites
Sources of data	Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting). 1) The capture system: The capture system is based on physician’s routine reporting of cancer cases. Physician’s complete and send forms: - Directly from their clinic; or - Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients 2) The recapture system: The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
Medical coding	The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3). The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor. The structure is C##.# M####/##, where: - C##.# specifies the primary site - M#### specifies the histology - /## specifies the behavior and the grade of the tumor
Reporting form	NCR reporting form

ATC	Name	B/G	Ingredients	Dosage	Form	Price
N07XX02	RILUTEK	B	Riluzole - 50mg	50mg	Tablet, film coated	15,886,212 L.L
N07XX02	RILUTEK	B	Riluzole - 50mg	50mg	Tablet, film coated	15,886,212 L.L
P01AB01	RAMAZOL	G	Metronidazole - 500mg	500mg	Tablet	216,359 L.L
R01AB08	RINOFLUIMUCIL	B	Acetylcysteine - 1%, Tuaminoheptane sulfate - 0.5%, Benzalkonium chloride - 0.0125%		Solution	419,279 L.L
R01AD08	RINISONA	G	Fluticasone propionate - 50mcg/actuation	50mcg/dose	Spray, suspension	556,351 L.L
R01AD11	RINEX	G	Triamcinolone acetonide - 55mcg/actuation	55mcg/actuation	Spray, suspension	712,876 L.L
R03AK10	RELVAR ELLIPTA	B	Vilanterol (trifenatate) - 25mcg/dose, Fluticasone furoate - 200mcg/dose		Inhalation powder	3,928,052 L.L
R03AK10	RELVAR ELLIPTA	B	Vilanterol (trifenatate) - 25mcg/dose, Fluticasone furoate - 100mcg/dose		Inhalation powder	3,928,052 L.L
R03DC03	RELIEFAST	G	Montelukast (sodium) - 4mg	4mg	Tablet, chewable	1,034,119 L.L
R03DC03	ROMILAST	G	Montelukast (sodium) - 5mg	5mg	Tablet, mouth dissolving	518,723 L.L
R03DC03	RELIEFAST	G	Montelukast (sodium) - 5mg	5mg	Tablet, chewable	1,034,119 L.L
R03DC03	ROMILAST	G	Montelukast (sodium) - 10mg	10mg	Tablet, film coated	228,453 L.L
R03DC03	RELIEFAST	G	Montelukast (sodium) - 10mg	10mg	Tablet, film coated	844,701 L.L
R03DC03	ROMILAST	G	Montelukast (sodium) - 4mg	4mg	Tablet, mouth dissolving	405,840 L.L
R05DB13	RAPICOD	G	Butamirate citrate - 0.15%	0.15%	Syrup	296,989 L.L
R06AE07	RINALGIT	G	Cetirizine (dihydrochloride) - 10mg/ml	10mg/ml	Drops solution	237,860 L.L
R06AX27	RINA 5	G	Desloratadine - 5mg	0.5mg/ml	Tablet, film coated	134,384 L.L
R06AX27	RINA	G	Desloratadine - 0.5mg/ml	0.5mg/ml	Syrup	159,917 L.L
R06AX28	RUPATADINE BIOGARAN	G	Rupatadine - 10mg	10mg	Tablet	341,336 L.L
S01XA18	RESTASIS	B	Ciclosporin - 0.5mg/ml	0.05%	Emulsion	4,100,063 L.L
S01XA18	RESTASIS	B	Ciclosporin - 0.5mg/ml	0.05%	Emulsion	4,100,063 L.L
V03AE01	RESINSODIO	G	Sodium polystyrene sulphonate - 99.75g/100g	99.75g/100g	Powder for suspension	1,534,668 L.L
V03AE02	RENVELA	B	Sevelamer - 800mg	800mg	Tablet, film coated	8,386,876 L.L

National Cancer Registry (NCR)